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Abstract
Objectives: To identify and implement strategies that help meet safety monitoring requirements in the context of
an observational study for artemether-lumefantrine (AL) administered as first-line treatment for uncomplicated
malaria in rural Tanzania.
Methods: Pharmacovigilance procedures were developed through collaboration between the investigating bodies,
the relevant regulatory authority and the manufacturer of AL. Training and refresher sessions on the
pharmacovigilance system were provided for healthcare workers from local health facilities and field recorders of
the Ifakara Health Demographic Surveillance System (IHDSS). Three distinct channels for identification of adverse
events (AEs) and serious adverse events (SAEs) were identified and implemented. Passive reporting took place
through IHDSS and health care facilities, starting in October 2007. The third channel was through solicited
reporting that was included in the context of a survey on AL as part of the ALIVE (Artemether-Lumefantrine In
Vulnerable patients: Exploring health impact) study (conducted only in March-April 2008).
Results: Training was provided for 40 healthcare providers (with refresher training 18 months later) and for six field
recorders. During the period 1
st September 2007 to 31
st March 2010, 67 AEs were reported including 52 under AL,
five under sulphadoxine-pyrimethamine, one under metakelfin, two after antibiotics; the remaining seven were due
to anti-pyretic or anti-parasite medications. Twenty patients experienced SAEs; in 16 cases, a relation to AL was
suspected. Six of the 20 cases were reported within 24 hours of occurrence.
Discussion: Safety monitoring and reporting is possible even in settings with weak health infrastructure. Reporting
can be enhanced by regular and appropriate training of healthcare providers. SMS text alerts provide a practical
solution to communication challenges.
Conclusion: Experience gained in this setting could help to improve spontaneous reporting of AEs and SAEs to
health authorities or marketing authorization holders.
Background
Spontaneous reporting of suspected adverse drug reac-
tions (ADRs) utilizing post-marketing surveillance or
pharmacovigilance techniques during drug therapy is less
applicable in many sub-Saharan African countries [1].
Pharmacovigilance is the science and activities relating to
the detection, assessment, understanding and prevention
of adverse effects or any other drug-related problem [2].
Pharmacovigilance plays a key role in ensuring that
p a t i e n t sr e c e i v es a f ed r u g s .T h ek n o w l e d g eo fad r u g ’s
adverse effects can be increased by various means,
including spontaneous reporting, intensive monitoring
and database studies [3]. Post-marketing surveillance -
which is often used synonymously for pharmacovigilance
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tant component of safety monitoring for drugs after they
have been licensed for use. Detailed data on adverse
events (AEs) are collected during the controlled clinical
trials that are required for licensing, but however rigor-
ous this process, the information collected cannot be
regarded as entirely comprehensive due to the relatively
restricted number of patients involved [1] and the exclu-
sion criteria that are frequently applied, for example to
omit pregnant women, young children, or elderly patients
[5]. Accordingly, post-marketing surveillance, especially
in the context of observational studies, can be a valuable
source of additional safety data within a large patient
population in a real-world setting.
The main factors limiting the implementation of phar-
macovigilance in resource-limited settings include lim-
ited access to healthcare facilities, availability of most
prescription drugs from the informal market, poor label-
ing of medications, high levels of illiteracy, poor record-
keeping, a shortage of qualified healthcare professionals
and a lack of awareness among healthcare workers of
the need to identify and report suspected ADRs that
occur during drug therapy. Post-marketing surveillance,
including monitoring of anti-malarial drugs, is currently
not undertaken in most sub-Saharan countries. A few
countries in the region, including Tanzania, have mana-
ged to introduce a system of yellow cards, but this
reporting process is still inefficient. Therefore, the bene-
fits of pharmaco-epidemiological studies with planned,
protocol-mandated collection of safety data may be par-
ticularly relevant in this region. However, careful atten-
tion must be paid to strategies that help to achieve
effective safety monitoring during such studies.
Failure to properly assess the safety of a widely used
drug such as a first-line anti-malarial treatment could
result in public misperception and lead to problems
with acceptability. This was seen in recent years with
sulphadoxine-pyrimethamine (SP) [6]. Concerns about
SP-related serious adverse skin reactions (e.g. Stevens-
Johnson syndrome) led to unnecessary delays in the pro-
cess of policy change in several African countries [7]. At
the time, it was difficult for Ministries of Health to pro-
vide evidence-based information to the media and the
public, and as a result public suspicion lingered for a
long time.
Since then, following recommendations from the
WHO that artemisinin-based combination therapy
(ACT) be used as first-line treatment of uncomplicated
malaria [8], artemether-lumefantrine (AL, Coartem®,
Novartis Pharma AG, Basel, Switzerland) has been
widely adopted throughout sub-Saharan Africa as first-
line treatment for uncomplicated Plasmodium falci-
parum malaria. The efficacy and safety of AL have been
extensively documented in clinical trials [9-14], but
safety data for AL are currently limited when deployed
on a large scale outside controlled clinical trials.
In November 2006, Tanzania adopted AL as first-line
anti-malarial therapy as part of its national policy. Fol-
lowing this decision, the ALIVE (Artemether-Lumefan-
trine In Vulnerable patients: Exploring health impact)
study was initiated to evaluate the impact of implement-
ing AL as first-line malaria treatment in a rural,
malaria-endemic region of the country. ALIVE is an
observational study undertaken by the Ifakara Health
Institute (IHI) and the Swiss Tropical and Public Health
Institute, and sponsored by Novartis Pharma AG and
the Novartis Foundation for Sustainable Development.
As for any study of this type, specific requirements for
safety monitoring were specified in the protocol, but the
challenges in meeting these requirements were
recognized.
This paper describes how the pharmacovigilance
requirements of the ALIVE study were being addressed
through innovative initiatives that included dedicated
training of relevant healthcare workers and community
longitudinal demographic surveillances recorders. The
use of short message service (SMS) text alerts was also
encouraged. This may provide a potential model to
ensure compliance with safety reporting requirements in
other observational studies or more general post-mar-
keting surveillance programmes.
Methods
The ALIVE study
ALIVE is a prospective, observational, community-based,
longitudinal, demographic surveillance study in adults
and children, undertaken to assess the impact of AL on
malaria morbidity and mortality in a rural, malaria-
e n d e m i ca r e ao fT a n z a n i aw h e nu s e da sf i r s t - l i n et r e a t -
ment for uncomplicated malaria. Since first-line use of
AL was adopted in Tanzania as national treatment pol-
icy in late 2006, it has been distributed to health facil-
ities for use twice daily for three days to all patients
≥3 months of age with a clinical diagnosis of uncompli-
cated malaria. The first dose is administered under
supervision at the health facility.
The primary objective of the study is to assess the
effect of AL on all-cause mortality in infants and chil-
dren aged ≥3 months (and >5 kg) and <5 years old com-
pared to historical data using SP. Secondary objectives
include the assessment of overall and malaria-related
health facility attendance rate in children and in adults.
This study also provided a framework for assessment of
patient satisfaction, adherence to the AL regimen in
both children and adults using a structured question-
naire, and safety monitoring of AL [15].
The study is taking place over a five-year period
(2007-2011) in two rural districts of Tanzania (Ulanga
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prises the population of the Ifakara Health Demo-
graphic Surveillance System (IHDSS) in the Ulanga
and Kilombero Districts, which numbered approxi-
mately 82,000 at the start of the study. The study area
is characterized by monsoon tropical rains that fall
from December to May, leading to an average annual
rainfall of 1,200 mm. Malaria transmission ranges from
intense to moderate and transmission is perennial,
peaking after the period of long rains with little seaso-
n a lv a r i a t i o n[ 1 6 ] .A c r o s st h es t u d ya r e at h e r ea r e2 5
villages and 25 health facilities that include health
posts, dispensaries, health centres and hospitals, with
varying quality of care.
The ALIVE study is conducted in compliance with the
Declaration of Helsinki following approval by the insti-
tutional review board of IHI and the Tanzanian National
Institute for Medical Research (NIMR).
Ifakara health demographic surveillance system
The IHI runs a well-established demographic surveillance
system covering parts of the Ulanga and Kilombero dis-
tricts in the ALIVE study, whereby standardized informa-
tion on pregnancies, births, deaths and migrations are
collected every four months by trained field recorders
who visit each of the approximately 19,000 households in
the surveillance areas of the two districts [17]. A com-
plete household survey is performed annually to update
the IHDSS database with socioeconomic and other key
indicators. The IHDSS is being used to collect selected
outcomes data in the context of the ALIVE study. The
IHDSS unit is part of the Indepth-Network, a global net-
work of 37 field sites in Africa and Asia focused on health
and population research [18].
Pharmacovigilance monitoring
In the context of this study, an AE is defined as ‘unfa-
vourable and unintended sign including an abnormal
laboratory finding, symptom or disease associated with
the use of a medical treatment or procedure, regardless
of whether it is considered related to the medical treat-
ment or procedure, that occurs during the course of the
study’. A serious adverse event (SAE) is defined as ‘an
undesirable sign, symptom or medical condition which is
fatal or life-threatening, requires or prolongs hospitaliza-
tion, results in persistent or significant disability/incapa-
city, constitutes a congenital abnormality or a birth
defect, is medically significant, or may jeopardize the
subject and may require medical or surgical intervention
to prevent one of the outcomes listed previously’. A sus-
pected causality assessment is defined as follows: ‘The
temporal relationship of the clinical event to trial drug
administration makes a causal relationship possible, and
other drugs, therapeutic interventions or underlying
conditions do not provide a sufficient explanation for the
observed event’.
The protocol included three channels through which
AEs and/or SAEs can be identified and reported (Figure
1), to ensure that reporting is compliant with the regula-
tions of the Tanzanian Food and Drugs Authority
(TFDA) and with standard operating procedures of
Novartis, the manufacturer of AL and the study sponsor.
Of these, the first two channels (IHDSS and health facil-
ities) employ passive pharmacovigilance while the third
(patient satisfaction/adherence survey) actively solicits
information on AEs and SAEs. Standard reporting forms
from the TFDA were used to collect data on AEs. Stan-
dard Novartis SAE forms were, in addition, used to
report SAEs.
Safety data from patients of all ages were reported
1. IHDSS (Level I). Field reporters in the IHDSS (who
are permanent residents in the area) have been
instructed that for any AL-associated AE (regardless of
seriousness) spontaneously brought to their attention,
they should complete a TFDA form, and recommend to
the reporter/patient that the event be reported to the
health facility. The TFDA form is delivered to the local
health facility, where additional details are added if pos-
s i b l e .I nt h ee v e n to fa nS A E ,aN o v a r t i sS A Ef o r mi s
additionally completed, and the SAE is assessed for
causality by the physician and forwarded to Novartis.
Additionally, in the event of an SAE being identified by
IHDSS reports, IHDSS interviewers are trained to advise
the patient to attend the local health facility
immediately.
2. Health facilities (Level II). Health professionals
working in health facilities (i.e. medical officers, pharma-
cists, clinical/maternal and child health nurses, or
laboratory staff) have also been instructed to complete a
TFDA form for any spontaneously reported AL-asso-
ciated AE, regardless of seriousness. In the event of an
SAE, a Novartis SAE form is additionally completed.
Assessment of causality by the treating physician is
undertaken. If AL is administered during pregnancy, a
specific Novartis pregnancy form is completed.
3. Patient satisfaction/adherence survey (Level III).
During the patient satisfaction/adherence survey that
involved 552 malaria patients and was conducted
between March-April 2008, information was actively
solicited on AEs and SAEss, and recorded on the TFDA
form (AEs) and the Novartis SAE form [15]. If an SAE
is suspected after assessment by a treating physician, the
form is submitted to Novartis.
The TFDA forms are collected monthly from health
facilities and transmitted to the TFDA safety desk in
Dar es Salaam by postal mailing.
From Ifakara, all SAE forms are transmitted to the
local East African Novartis safety office, by fax or email.
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held at the IHI. The ALIVE safety coordinator also
actively follows up the patients for verification and
assessment and, if necessary, the safety coordinator
refers the patient to a health facility for further assess-
ment and management. In the event of incomplete
information from the relevant healthcare providers, the
ALIVE coordinator may visit the patient and complete
all necessary forms on site. All TFDA and Novartis SAE
forms are also forwarded to the TFDA (Figures 1 and 2).
The TFDA form requires standard reporting informa-
tion (e.g. patient demographics, description of the event,
suspected and concomitant drug(s), management and out-
come of the event etc). The Novartis SAE form, which was
field-tested by IHDSS and was found to be consistent with
the TFDA report form, requires information on the diag-
nosis and description of the event, how the event met cri-
teria for classification as a SAE, treatment doses at or
before onset of the SAE, therapy dates, past medical his-
tory, relevant concomitant drugs, relevant laboratory
values, investigator’s causality assessment (i.e. suspected
[possibly or probably related to study drug] or not sus-
pected) and outcome. If a causality assessment is missing
when an SAE is reported either at a health facility or dur-
ing the patient satisfaction/adherence survey, the SAE
form is sent to Novartis for provisional reporting.
SMS reporting
In order to ensure timely reporting of AEs and SAEs,
IHDSS field recorders or health facility staff were
encouraged to send a mobile telephone SMS text alert
to the ALIVE safety coordinator immediately when an
AE or SAE is identified, prior to submitting the physical
reporting form. The SMS includes a summary of patient
demographics, date and type of event. Using this infor-
mation, the safety coordinator then uses SMS texting to
alert the local East African Novartis safety office and as
necessary sends a fax or scanned copy of the initial
report by email. Reminders to IHDSS field reporters and
staff at health facilities that completed forms are
required within the proscribed time frame (i.e. initial
report within 24 hours of event and follow-up report
not later than 15 days after the initial report) are also
sent through SMS alerts.
Training for healthcare workers
In October 2007, a one-day training session was pro-
vided for healthcare providers from health facilities
located in the two districts in which the ALIVE study
was undertaken. Participants were divided in to two
groups, each trained separately once during each of
the two consecutive training days. Each session com-
prised at least 35 persons, from both of the districts
that host IHDSS (Kilombero and Ulanga). This training
was conducted jointly by facilitators from the investi-
gating bodies (IHI and the Swiss Tropical and Public
Health Institute), the regulatory authority (TFDA) and
the drug manufacturer (Novartis Pharma AG). Trai-
nees were designated as focal persons for their health
facilities after training. During the training session,
Figure 1 Reporting channels for adverse events (AE). IHDSS, Ifakara Health Demographic Surveillance System; TFDA, Tanzanian Food and
Drugs Authority; HH, Household; HF, Health Facility; SAS, Satisfaction/Adherence Survey.
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SAEs, procedures for completing the relevant forms,
and the reporting channels (Table 1). All reporting
forms were presented and delegates were shown
how to complete each one in a step-by-step process.
Plenary presentations were followed by small-group
breakout sessions in which case studies provided an
insight into the identification and handling of AEs and
SAEs and how to report them in a timely manner in
compliance with the requirements of TFDA and
Novartis. Delegates received training materials, hand-
outs and copies of all relevant reporting forms.
Eighteen months later (April 2009) another very simi-
lar training session was undertaken by experts from
Novartis Pharma AG, Swiss Tropical and Public Health
Institute, IHI and TFDA. This training included more
details and emphasis on expedited reporting and causal-
ity assessments.
A similar package of training materials was also pro-
vided to IHDSS field recorders individually in the field
by the ALIVE safety coordinator. In addition, a retrain-
ing session was provided for IHDSS field recorders,
again undertaken by IHI with materials developed
jointly by the Swiss Tropical and Public Health Institute,
the TFDA and Novartis. The session covered the defini-
tion of safety terms (AEs, ADRs and SAEs), explained
the reporting forms, and described the reporting
procedures.
Results
The first training session, in October 2007 was attended
by 40 healthcare providers from health facilities in the
study districts. The second training session was attended
by 35 healthcare providers, of whom more than half had
not attended the first training course because they had
recently been relocated from facilities outside the
Figure 2 Reporting channels for serious adverse events (SAE).I H D S S ,I f a k a r aH e a l t hD e m o g r a p h i cS urveillance System; TFDA, Tanzanian
Food and Drugs Authority; HH, Household; HF, Health Facility; SAS, Satisfaction/Adherence Survey.
Table 1 Content of training programme for healthcare
workers at health facilities
Topic Content
Study drug (AL) Indications and dosage
Contraindications
Drug interactions
Use in pregnancy/lactation
Common ADRs (frequency > 10%)
Special precautions
Study objectives Primary and secondary objectives of the
observational study (ALIVE)
ADRs, AEs & SAEs Minimum reporting requirements
Definitions of ADRs, AEs & SAEs (including
congenital abnormalities & birth defects)
Detection and recognition of ADRs, AEs & SAEs
Reporting of AEs
& SAEs
Data collection requirements
TFDA reporting form
Novartis SAE reporting form
ADR = adverse drug reaction; AE = adverse event; AL = artemether-
lumefantrine; ALIVE = Artemether-Lumefantrine In Vulnerable patients:
Exploring health impact; SAE = serious adverse event; TFDA = Tanzanian Food
and Drugs Authority. ADRs were defined as ‘all noxious and unintended
responses to a medicinal product related to any dose. The responses to a
medicinal product means that a causal relationship between a medicinal
product and an adverse event is at least a reasonable possibility i.e. the
relationship cannot be ruled out’.
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field recorders attended the IHDSS training session and
all IHDSS field recorders received reporting materials.
Pharmacovigilance activity from 1
st September 2007 to
31
st March 2010 is described in the following sections.
Within this period, 67 AEs were reported across the
total patient population, of which seven were identified
through Level I (passive surveillance), 59 through Level
II (passive surveillance) and the remainder through
Level III (active surveillance). Among the 59 AEs that
were reported through Level II, nearly 24% were expo-
sure to AL during pregnancy. Eleven exposures occurred
during the second trimester and the remaining three
occurred in the third trimester. One of the three AEs
that took place in the third trimester was a stillbirth,
which occurred four weeks after AL exposure during
the 34
th week of pregnancy with no suspected relation-
ship with AL. The other exposures were not associated
with any adverse pregnancy outcome. The reporting rate
peaked shortly after the first training course, subse-
quently declining until after the second training course
in April 2009 (Figure 3).
Of the 67 AEs reported, 52 occurred after AL therapy,
five after SP, one after metakelfin, and another one after
amodiaquine and paracetamol. Of the other AEs, one
occurred after penicillin injection, two after paracetamol,
four after ivermectin and one after administration of
amoxicillin. During the same period (1
st September 2007
to 31
st March 2010), a total of 181,609 patients with sus-
pected malaria reported to health facilities in the ALIVE
study area and received AL as first-line treatment for
malaria. The reporting rate of AL-associated AEs was
therefore 28.6 per 100,000 AL-exposed patients. The AEs
that were recorded after AL included vomiting (5 cases),
itching and/or rash (21 cases); difficulty breathing, con-
vulsion and headache occurred in 12 cases. The other 14
AEs recorded after AL administration, which occurred
alone or in combination, were high fever (2), dyspnoea
(2), fatigue (3), dizziness (2), paraplegia (1) and a swollen
eyelid (1). Others were insomnia (1), stiffness of joints
and neck (1) and dysuria (1). In all cases occurrences
were reversible and regressed with malaria symptoms.
The five AEs that occurred after SP were mild erythe-
matic skin lesions that did not progress to Stevens-John-
son syndrome. The AEs seen following treatment with
penicillin and amoxicillin were both rashes.
A total of 20 patients were reported who experienced
SAEs during September 2007 to March 2010 (Table 2). In
16 cases, a relation to AL was suspected. All but two
patients recovered; in the two cases where the patient died
and the one in which a stillbirth occurred, the SAE was
not classified as having a suspected relation to AL. Of the
20 patients with SAEs, 6 cases were notified to the ALIVE
safety database within 24 hours of occurrence. Twelve of
these cases were detected at the health facilities and seven
at home through IHDSS surveys (passive surveillance).
Only one case was detected at home during the patient
satisfaction/adherence survey (active surveillance) by a
research field interviewer and was thus reported directly
to the safety coordinator in Ifakara. Two patients died.
One was a 4-year-old child who died in hospital on the
third day after admission. The patient was diagnosed with
malaria at a secondary health care facility and given two
tablets of AL, then referred to the tertiary health care facil-
i t yw h e r es e v e r em a l a r i aw a sd i a g n o s e do nt h ed a yo f
referral, together with symptoms of convulsion and cough.
Figure 3 Number of adverse events (AEs) reported per month during 1
st September 2007 to 31
st March 2010 indicated on the left-
hand y-axis. The right-hand y-axis indicates the percentage of AL tablets prescribed per month, with the total number of AL tablets during 1
st
September 2007 to 31
st March 2010 as the denominator.
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Two days later, the patient died in the hospital, with the
verbal autopsy giving the cause of death as difficulty in
breathing. The second death occurred in an infant of five
months, who was initially treated with AL and amoxicillin
at a secondary health care facility one day before death.
On the next day the infant’s condition deteriorated and
AL discontinued, and the infant was then treated at the
nearby primary health care facility as a case of severe
malaria and pneumonia using quinine and penicillin injec-
tion. The patient was not referred to hospital on time and
as a result died at home due to severe respiratory distress.
Discussion
Observational studies such as ALIVE offer the opportu-
nity to obtain safety data on marketed drugs in settings
that extend beyond the relatively small and selected
populations that are assessed in randomized, controlled
clinical trials. Undertaking a prospective observational
study, however, requires careful consideration of how to
meet the protocol-specified safety monitoring require-
ments of the relevant health authorities and the manu-
facturer. Particular challenges are faced in establishing
pharmacovigilance monitoring in many rural areas of
sub-Saharan Africa, where existing health services and
patient access are often limited and often coupled with
low awareness and motivation of healthcare staff about
the need to report potential safety problems that occur
during drug treatment.
The current paper describes how a training pro-
gramme for healthcare personnel, accompanied by pro-
vision of training and reporting materials and the use of
SMS text alerts, was adopted to support the safety mon-
itoring for a large-scale prospective observational study
of the use of AL for uncomplicated P. falciparum
malaria in a rural area of Tanzania. The benefits of
training were demonstrated by the increased AE report-
ing rate observed after both initial and follow-up train-
ing sessions, and by the appropriate nature of the events
reported and adequacy of data provided. The decline in
Table 2 Patient characteristics, type, timing and outcomes of serious adverse events (SAEs) reported during 1
st
September 2007 to 31
st March 2010
Sex Age (years) SAE
a Interval between
event and recording
Outcome Level of
reporting
Female 37 Severe headache &
vomiting
1 days Recovered II
Female 12 Dyspnoea & vomiting 1 day Recovered II
Male 2 Twitching 1 days Recovered II
Female 4 Severe vomiting 4 days Recovered II
Female 2 Generalized itching/rash
b >60 days
a Recovered II
Female 1 Respiratory distress 3 days Died; not classified as suspected in Novartis
safety database
III
Female 4 Convulsion 9 days Died; not classified as suspected in Novartis
safety database
II
Female 46 Dyspnoea 1 day Recovered II
Male 38 Generalized rash
b 7 days Recovered II
Female 47 Generalized rash
b 1 day Recovered II
Male 13 Dyspnoea & swollen
eyelids
1 day Recovered II
Male 7 months Skin rashes 20 days Recovered I
Female 17 Paraplegia >60 days Recovered I
Female 5 Joint stiffness >60 days Recovered I
Male 10 Dizziness & headache 30 days Recovered I
Female 32 Skin rashes & amnesia >60 days Recovered I
Female 11 Skin rashes 60 days Recovered I
Male 7 Skin rashes 60 days Recovered I
Female 47 Skin Rashes 10 days Recovered II
Female 34 weeks
(gestational age)
Stillbirth >60 days Stillbirth; not classified as suspected in Novartis
safety database
II
All events were recorded following AL treatment and were classified as SAEs by presenting with any or all of the following: (a) fatal or life-threatening (b)
prolonging hospitalization (c) resulting in persistent or significant disability/incapacity (d) may jeopardize the subject or (e) may require medical or surgical
intervention to prevent one of the previous outcomes.
a Report was initially misplaced at the health facility and not made available to safety coordinator on time.
b Skin depigmentation for an extended period, which was considered to constitute significant incapacity Level of reporting: Level I, IHDSS; Level II, health
facilities; Level III, patient satisfaction/adherence survey.
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initial and follow-up training highlights the critical nat-
ure of repeated training and reminders. The upsurge in
AE reporting and subsequent downturn eight months
later is a significant cause for concern, especially for a
programme that has to be incorporated into the routine
health service delivery system. In particular, the type of
training session conducted in this study may not be sus-
tainable within the standard health service given the
inherent costs and time burden for the already over-
stretched system. In the ALIVE study, however, this
approach was adopted because there was no efficient
and cheaper comparable alternative. The view of the
a u t h o r si st h a tp h a r m a c o v igilance reporting must be
included in the curricula of medical schools and be part
of the job description of health care workers. Where
possible, it should be included in the health information
management system in the set up of developing coun-
tries to maximize capture of AEs. This work provides a
solid basis for a recently planned project to establish
pharmacovigilance reporting in eight sites in Burkina
Faso, Ghana, Mozambique and Tanzania: the INDEPTH
Phase IV Safety and Effectiveness Studies Platform
(INESS) [19].
For each AE reported, minimum reporting require-
ments were met, i.e. an identifiable reporter, an identifi-
able patient, a suspected product, and an AE. SAEs were
reported in 20 patients, of whom five were given intra-
venous quinine after referral to tertiary health facilities
and subsequently recovered, suggesting a missed diagno-
sis of complicated malariaf o rw h i c hA Lw a sn o tt h e
appropriate treatment [20]. Rash, as reported here in 21
cases, is a recognized and frequent AE associated with
artemesinin-based combination therapy [9,21-23]. There
were 14 cases of AL treatment reported in pregnant
women during the period described. For the single case
of stillbirth that occurred during AL exposure, medical
records were sparse which made the cause of stillbirth
difficult to establish. The mother may have been HIV-
positive. In addition, she was given quinine at week 32
of pregnancy, followed four days later by vaginal bleed-
ing and then stillbirth, suggesting that quinine may have
played a causative role.
A markedly lower reporting rate is routinely observed
in observational post-marketing studies that use passive
pharmacovigilance monitoring (whereby AEs are only
reported spontaneously by patients or carers to health
professionals) compared to clinical trials in which data
on AEs are collected actively, even in countries with
well-established spontaneous reporting systems [5,24].
In some sub-Saharan African countries, the challenge of
capturing safety data may be even more profound: in a
recent observational study of first-line AL use in rural
Ethiopia, not a single AE was reported spontaneously
over a two-year period despite over 200,000 individuals
presenting with suspected malaria [25]. Reporting rates
of AEs in the ALIVE study - which mainly relied on
passive pharmacovigilance - were higher than in the
Ethiopian study; however, they were still low taking into
account that over 180,000 AL treatments were adminis-
tered during the observation period. This may be partly
explained by the good overall safety profile of AL, with
most of the AEs observed in clinical trials being related
to malaria itself rather than to AL exposure [21,26].
Most of the AEs occurring after AL exposure in the cur-
rent study are similar in nature to those that were
observed in the pre-registration clinical trials of the
drug [21,27].
Most of the reports of AEs made under the ALIVE
pharmacovigilance programme reported in this paper
were captured through the passive surveillance route,
but it should be borne in mind that passive pharmacov-
igilance systems have various limitations. Passive phar-
macovigilance can be particularly challenging in poorly
educated, remote communities some distance from the
nearest health facility and with a low number of trained
healthcare workers. These factors are likely to have been
an important cause contributing to low reporting rates
in this study as well. Other passive monitoring initia-
tives, such as the promotion of ‘yellow cards’ in a rural
area of Mozambique [28] and a malaria pharmacovigi-
lance programme in South Africa [29] have also shown
low reporting rates (of ADRs), underscoring the chal-
lenge of effective safety data collection during anti-
malarial therapy in Africa outside the context of clinical
trials.
The use of active surveillance, with prospective follow-
up of the treated population, is ideal but unrealistic on a
large scale due to cost and manpower requirements. In
this study, however, active surveillance was applied only
during a survey that investigated the feasibility and
acceptability of AL during March-April 2008. The depth
of information that was obtained during the survey may
not be representative of standard pharmacovigilance
reporting as considered in this article, due to the short
duration of the survey. Notably, the aim of the ALIVE
feasibility study was primarily to assess the adherence to
and acceptability of AL, and results showed that patients
believed AL to be a good drug [15]. This could have
biased their judgment such that they did not report
minor AEs that might have occurred because this con-
flicted with their belief that the drug was excellent.
Using passive reporting it has been suggested that
reporting rates could be improved by providing non-
financial incentives to community members and health-
care workers and ensuring confidentiality [30]. It has
also been proposed that the lack of local expertise in
pharmacovigilance could be tackled through developing
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agencies and sharing of best practice, with the long-
term goal that each country should establish its own
national pharmacovigilance system that would contri-
bute to a global database such as that held by the
Uppsala Monitoring Centre [31].
The pharmacovigilance monitoring established for this
study had the advantage of being a joint initiative
between the investigators, the relevant drug regulatory
authority and the sponsor (here, as in many instances,
the drug manufacturer) - an approach which has
recently been advocated [30,31]. This resulted in a valu-
able combination of local knowledge, utilization of an
existing healthcare and technical infrastructure, regula-
tory skills, funding, and experience of safety monitoring
and data management. Additionally, training and the
provision of materials spanned all levels of healthcare
personnel although the decline in AE reporting during
the 18-month delay between initial training and follow-
up training may indicate that more frequent repetition
of training, with regular reminders, could have increased
the number of events reported. Prompt training of new
healthcare staff would also be beneficial. Lastly, use of
SMS texts to notify the ALIVE safety database coordina-
tor at the time an AE was identified ensured prompt
data capture and guaranteed that the event would not
be lost during its progress through the subsequent
reporting channels.
In the ALIVE pharmacovigilance system reported
h e r e ,i tw a so b s e r v e dt h a tm o s tA E sr e s o l v e di np a r a l l e l
with improvement in the treated clinical malaria. How-
ever, the relatively short half-life of artemether indicates
that if an AE were related to the drug, drug clearance
would have coincided with clearance of parasites (and
host-response inflammatory markers) [32,33]. Lumefan-
trine, in contrast, has an extended half-life of 4-6 days
[34]. Because this study included neither measurement
of artemether or lumefantrine plasma concentration nor
ascertainment of parasitaemia at recovery, it is likely
that these AEs were related to malaria but the contribu-
tion of treatment cannot be excluded.
In conclusion, this article presents a practical model
for pharmacovigilance monitoring during a prospective
observational study that is applicable for rural commu-
nity settings in sub-Saharan Africa or other developing
regions. Training of healthcare workers at all levels to
support protocol-mandated safety monitoring require-
ments was straightforward to undertake and showed a
positive impact on the identification and safety report-
ing, but more frequent refresher courses and reminders
are required to optimize and sustain reporting levels
over time. Use of SMS texts is a pragmatic solution to
communication challenges and helps to avoid lost or
delayed reports. Finally, a collaborative approach
involving all major participants - investigators, sponsor
and regulatory authorities - from the outset offers a
valuable template for future studies and facilitates sensi-
tization of healthcare workers to the need for safety
reporting. It is the authors’ view that these strategies
could support the achievement of safety monitoring
requirements during an observational study. Moreover,
they could contribute to improvements in ongoing
spontaneous reporting of AEs to health authorities, mar-
keting authorization holders and the WHO Collaborat-
ing Centre for International Drug Monitoring (the
Uppsala Monitoring Centre) [35] in regions with limited
experience of pharmacovigilance monitoring and in
which local resources are restricted.
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